On March 10, 2022 Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for the treatment of advanced and metastatic cancers, reported that it has been awarded grant funding as part of Round 3 of the New Jersey Commission on Science, Innovation, and Technology Direct Financial Assistance component (Phase I&II) of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer Program (STTR) (Press release, Manhattan BioSolutions, MAR 10, 2022, View Source [SID1234609874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This award will enable early-stage preclinical validation of therapeutic leads previously supported by the SBIR and STTR Phase I grants. Novel therapeutic platforms developed by Manhattan BioSolutions leverage pathogen-specific immune responses to fight disease, particularly cancers. Dr. Borys Shor, CEO of Manhattan BioSolutions, commented: "This award expands our capacity to discover novel therapies at the intersection of innate immunity, age-related diseases, and cancer. We expect to have a deep pipeline of discovery stage products by year-end and bring those into human trials in 2023."

On March 10, 2022 MorphoSys AG (FSE: MOR; NASDAQ: MOR) reported that it will account for a non-cash impairment charge on goodwill in the amount of approximately € 231 million (Press release, MorphoSys, MAR 10, 2022, View Source [SID1234609873]). This write-down results from the consolidation of the Company’s research and discovery activities after the acquisition of Constellation Pharmaceuticals, Inc. ("Constellation"). MorphoSys decided to focus its research activities on the most advanced programs and to centralize all laboratory activities at its German research hub in Planegg, Germany. Consequently, all US-based activities relating to discovery biology and drug discovery departments were discontinued. Therefore, early pipeline projects cannot be realized anymore and the expected cash flows from these projects will not materialize accordingly. Since the early pipeline was part of the goodwill resulting from the acquisition of Constellation, an impairment test was performed based on the latest cash flow projections, which triggered an impairment charge on the goodwill in the amount of € 231 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The write-down has no cash effect and will impact Group operating expenses for the fourth quarter of the year 2021. The write-down of € 231 million will be additive to the Group operating expenses which will be published on March 16, 2022 along with the full results for the fourth quarter and full year 2021.

On March 10, 2022 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, reported that management will participate in a fireside chat at the 34th Annual Roth Conference on March 14, 2022, at 11:30AM PT (Press release, Panbela Therapeutics, MAR 10, 2022, View Source [SID1234609872]). The webcast will be available at: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected].

About SBP-101

SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, demonstrating a median overall survival (OS) of 12.0 months which is not yet final, and an objective response rate (ORR) of 48%, both exceeding what is seen typically with the standard of care of gemcitabine + nab-paclitaxel suggesting potential complementary activity with the existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Serious visual adverse events have been evaluated and patients with a history of retinopathy or at risk of retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the current Panbela sponsored clinical trial provides support for continued evaluation of SBP-101 in a randomized clinical trial. For more information, please visit
View Source .

On March 10, 2022 Novartis reported that it has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors (Press release, Novartis, MAR 10, 2022, View Source [SID1234609871]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the initial agreement, the Carisma Therapeutics manufacturing process will be transferred to the Novartis Cell Therapy Site in Morris Plains, U.S, starting in the coming days. Clinical manufacturing is planned to begin in 2023.

"The Global Biotech Cooperations unit of Novartis is fully committed to collaborate with Carisma Therapeutics to bring their CAR-M cell therapy to patients by offering its proven state-of-the art cell and gene production capabilities," said Anton Gerdenitsch, Head of the Contract Manufacturing Organization at Novartis Technical Operations. "As one of the world’s largest producers of medicines, Novartis can mobilize its manufacturing capacity in an efficient way on multiple fronts."

This new agreement follows contract manufacturing agreements signed last year such as the agreements with BioNTech, for the filling of the Covid vaccine at the Novartis Technical Operations’ sites in Stein, Switzerland, and in Ljubljana, Slovenia.

Novartis continues to offer its world-class capabilities to other companies to take over manufacturing activities including a variety of technologies such as mRNA production and others. Further specifics will be disclosed when agreements are concluded.

On March 10, 2022 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported that it will present at the 34th annual Roth Conference on Monday, March 14, 2022, at 3:30 PM PT (Press release, Delcath Systems, MAR 10, 2022, View Source [SID1234609870]). A webcast of the presentation will be available at: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected].